Gland Pharma Q2 revenue rises 23% to INR18,336 million as profit jumps 58%
AI Summary- Gland Pharma reported Q2 FY27 revenue growth, with EBITDA and PAT rising year over year.
- INR18,336 million was Q2 revenue, up 23%, while PAT rose 58% to INR2,908 million.
- Cenexi posted a EUR6 million EBITDA loss after planned shutdowns, with profitability expected from Q3.